C. Michael Gibson MD

@CMichaelGibson

Oct 24

Boston Business Journal@BosBizJournal

Oct 23

MGB's last round of layoffs focused on administrative roles. Now the health system is looking to restructure clinical departments. bizjournals.com/boston/news/20…

Francis Deng, MD

@francisdeng

Oct 14

Balázs Pozsgay

@pozsgaybalazs

Oct 13

We had an online seminar recently. The speaker mentioned an open problem at the end of the talk, which would be a natural continuation of the published work. It seemed like a good problem. It asks whether or not a certain construction can exist. Well defined, natural, nice.

I asked Astra. It solved the problem after 2-3 prompts. The first solution (a concrete example) seems too simple, so I asked Astra to find something more complicated. Now there is a second example.

I asked Astra to explain to me why the solution works, this happened on the way back home from work. Travel on the tram and the metro used efficiently.

At home I also asked Astra to compile a research article. The end result is a good starting point for a paper. Of course it looks like AI slop, but it is way less slop then what earlier models would produce. It would take only a few days of concentrated work to make an actual journal quality paper out of it.

All of this feels... illegal, pointless, and exciting at the same time. So many conflicting emotions.

What do we gain from all of this? Should we publish papers? Or just shout into the world that we know an answer? I am really not sure.

Naturally, I informed the speaker, he was interested. I sent him the document. I am waiting for the answer.

Minimal efforts, some understanding, and now a new result that would seem non-trivial for most of my colleagues. A new paper that had been welcome and appreciated at any time pre-AI.

Where do we really go from here...

Jay Giri@jaygirimd

Oct 11

Sam Margolis

@sammargolis_

Oct 8

🧬 Training and evaluating AI scientists on drug target discovery is hard.

We introduce DrugTargetWorld: Synthetic Biomedical Worlds for Training and Benchmarking AI Scientists

The environment turns end-to-end drug target discovery into a problem where AI scientists can be l truth.

🎯 We’ve been able to hill climb on problems like Chess, Go, StarCraft, and even now computer science and mathematics because they have a verifiable reward.

We want to bring that to drug discovery.

Built with @BGomes_1905 @euanashley and an incredible team at Stanford and beyond.

Rishi Wadhera, MD MPP

@rkwadhera

Oct 9

Sundar Pichai

@sundarpichai

Oct 8

Today @TheLancet published our AMIE study with @BIDMC_Medicine, the first prospective study of patient-facing conversational diagnostics in a real clinic.

AMIE is a research system people can chat with before doctors appointments. Testing AMIE outside the lab with real urgent w technology can help gather medical histories safely. Clinicians reported that the summaries helped them prepare for visits in 75% of cases and influenced their approach to care in more than half. AMIE’s differential diagnoses also matched the doctors’ final diagnoses 90% of the time giving clinicians more time to focus on patient care.

It’s Google’s first-ever paper in The Lancet’s main journal!